PERFOROMIST® (formoterol fumarate) Inhalation Solution is used for the long-term treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both. It is only to be used with a standard jet nebulizer attached to an air compressor and is taken twice daily (morning and evening).

The recommended dose of PERFOROMIST Inhalation Solution is one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose greater than 40 mcg is not recommended.1

  • PERFOROMIST must be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor.1

  • PERFOROMIST should always be stored in the foil pouch and removed only immediately before use. Contents of any partially used container should be discarded.1

  • The drug compatibility (physical and chemical), efficacy and safety of PERFOROMIST Inhalation Solution when mixed with other drugs in a nebulizer have not been established.1

  • If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be re-evaluated.1

Dosage Forms and Strengths


PERFOROMIST (formoterol fumarate) Inhalation Solution is supplied as a sterile solution for nebulization in low-density polyethylene unit-dose vials. Each vial contains formoterol fumarate dihydrate, USP equivalent to 20 mcg/2 mL of formoterol fumarate.1



The expected signs and symptoms with overdosage of PERFOROMIST Inhalation Solution are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms listed under the Adverse Reactions section of the full Prescribing Information. Signs and symptoms may include angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of PERFOROMIST Inhalation Solution.

Treatment of overdosage consists of discontinuation of PERFOROMIST Inhalation Solution together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of PERFOROMIST Inhalation Solution. Cardiac monitoring is recommended in cases of overdosage.1

For additional information about overdose treatment, call a poison control center (1-800-222-1222).

PERFOROMIST can be used in ANY standard jet nebulizer:

  • Doesn’t require hand-breath coordination — calm, deep, even breathing is sufficient1
  • Modern nebulizers can be portable and battery-operated9
  • PERFOROMIST can be stored in room temperature for up to 3 months1
    - Longer than any other nebulized LABA

Consider asking patients periodically to demonstrate how they use their inhaler or nebulizer, including set up and clean up, to check for proper technique.

Learn more about PERFOROMIST efficacy and safety.